Advances in liquid biopsy approaches for early detection and monitoring of cancer

doi:10.1186/s13073-018-0533-6

. 2018 Mar 20;10(1):21.

doi: 10.1186/s13073-018-0533-6.

Advances in liquid biopsy approaches for early detection and monitoring of cancer

Anna Babayan¹, Klaus Pantel²

Affiliations

¹ Department of Tumor Biology, University Medical Center Hamburg-Eppendorf, Martinistraße 52, 20246, Hamburg, Germany. a.babayan@uke.de.
² Department of Tumor Biology, University Medical Center Hamburg-Eppendorf, Martinistraße 52, 20246, Hamburg, Germany. pantel@uke.de.

PMID: 29558971
PMCID: PMC5861602
DOI: 10.1186/s13073-018-0533-6

Advances in liquid biopsy approaches for early detection and monitoring of cancer

Anna Babayan et al. Genome Med. 2018.

. 2018 Mar 20;10(1):21.

doi: 10.1186/s13073-018-0533-6.

Authors

Anna Babayan¹, Klaus Pantel²

Affiliations

¹ Department of Tumor Biology, University Medical Center Hamburg-Eppendorf, Martinistraße 52, 20246, Hamburg, Germany. a.babayan@uke.de.
² Department of Tumor Biology, University Medical Center Hamburg-Eppendorf, Martinistraße 52, 20246, Hamburg, Germany. pantel@uke.de.

PMID: 29558971
PMCID: PMC5861602
DOI: 10.1186/s13073-018-0533-6

Abstract

Progress in sensitive analytical approaches has opened new avenues for the detection of cells or products such as circulating cell-free DNA released by tumors. These 'liquid biopsies' are being explored in clinical trials for early cancer detection, prediction of recurrent disease, and assessment of therapeutic resistance mechanisms.

Keywords: Biomarker; Circulating tumor cells; Early detection; Liquid biopsy; Minimal residual disease; ctDNA.

PubMed Disclaimer

Conflict of interest statement

Competing interests

The authors declare that they have no competing interests.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Cited by

Development and evaluation of safety and effectiveness of novel cancer screening tests for routine clinical use with applications to multicancer detection technologies.
Doubeni CA, Lau YK, Lin JS, Pennello GA, Carlson RW. Doubeni CA, et al. Cancer. 2022 Feb 15;128 Suppl 4(Suppl 4):883-891. doi: 10.1002/cncr.33954. Cancer. 2022. PMID: 35133658 Free PMC article.
The Practicality of the Use of Liquid Biopsy in Early Diagnosis and Treatment Monitoring of Oral Cancer in Resource-Limited Settings.
Adeola HA, Bello IO, Aruleba RT, Francisco NM, Adekiya TA, Adefuye AO, Ikwegbue PC, Musaigwa F. Adeola HA, et al. Cancers (Basel). 2022 Feb 23;14(5):1139. doi: 10.3390/cancers14051139. Cancers (Basel). 2022. PMID: 35267452 Free PMC article. Review.
Using All Our Genomes: Blood-based Liquid Biopsies for the Early Detection of Cancer.
Adams E, Sepich-Poore GD, Miller-Montgomery S, Knight R. Adams E, et al. View (Beijing). 2022 Jan;3(1):20200118. doi: 10.1002/VIW.20200118. Epub 2022 Jan 31. View (Beijing). 2022. PMID: 35872970 Free PMC article.
Advancing Biomarker Development Through Convergent Engagement: Summary Report of the 2nd International Danube Symposium on Biomarker Development, Molecular Imaging and Applied Diagnostics; March 14-16, 2018; Vienna, Austria.
Lim MS, Beyer T, Babayan A, Bergmann M, Brehme M, Buyx A, Czernin J, Egger G, Elenitoba-Johnson KSJ, Gückel B, Jačan A, Haslacher H, Hicks RJ, Kenner L, Langanke M, Mitterhauser M, Pichler BJ, Salih HR, Schibli R, Schulz S, Simecek J, Simon J, Soares MO, Stelzl U, Wadsak W, Zatloukal K, Zeitlinger M, Hacker M. Lim MS, et al. Mol Imaging Biol. 2020 Feb;22(1):47-65. doi: 10.1007/s11307-019-01361-2. Mol Imaging Biol. 2020. PMID: 31049831
Role of non-coding RNA in lineage plasticity of prostate cancer.
Tan W, Xiao C, Ma M, Cao Y, Huang Z, Wang X, Kang R, Li Z, Li E. Tan W, et al. Cancer Gene Ther. 2025 Jan;32(1):1-10. doi: 10.1038/s41417-024-00834-z. Epub 2024 Nov 4. Cancer Gene Ther. 2025. PMID: 39496938 Review.

See all "Cited by" articles

References

1. Pantel K, Alix-Panabieres C. Circulating tumour cells in cancer patients: challenges and perspectives. Trends Mol Med. 2010;16:398–406. doi: 10.1016/j.molmed.2010.07.001. - DOI - PubMed
1. Bardelli A, Pantel K. Liquid biopsies, what we do not know (yet) Cancer Cell. 2017;31:172–179. doi: 10.1016/j.ccell.2017.01.002. - DOI - PubMed
1. Berghuis AM, Koffijberg H, Prakash J, Terstappen LW, IJzerman MJ. Detecting blood-based biomarkers in metastatic breast cancer: a systematic review of their current status and clinical utility. Int J Mol Sci. 2017;18(2) 10.3390/ijms18020363. - PMC - PubMed
1. Ulrich BC, Paweletz CP. Cell-free DNA in oncology: gearing up for clinic. Ann Lab Med. 2018;38:1–8. doi: 10.3343/alm.2018.38.1.1. - DOI - PMC - PubMed
1. Cohen JD, Li L, Wang Y, Thoburn C, Afsari B, Danilova L, et al. Detection and localization of surgically resectable cancers with a multi-analyte blood test. Science. 2018;359:926–930. doi: 10.1126/science.aar3247. - DOI - PMC - PubMed

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
Other Literature Sources
- scite Smart Citations

[1] Pantel K, Alix-Panabieres C. Circulating tumour cells in cancer patients: challenges and perspectives. Trends Mol Med. 2010;16:398–406. doi: 10.1016/j.molmed.2010.07.001. - DOI - PubMed

[2] Pantel K, Alix-Panabieres C. Circulating tumour cells in cancer patients: challenges and perspectives. Trends Mol Med. 2010;16:398–406. doi: 10.1016/j.molmed.2010.07.001. - DOI - PubMed

[3] Bardelli A, Pantel K. Liquid biopsies, what we do not know (yet) Cancer Cell. 2017;31:172–179. doi: 10.1016/j.ccell.2017.01.002. - DOI - PubMed

[4] Bardelli A, Pantel K. Liquid biopsies, what we do not know (yet) Cancer Cell. 2017;31:172–179. doi: 10.1016/j.ccell.2017.01.002. - DOI - PubMed

[5] Berghuis AM, Koffijberg H, Prakash J, Terstappen LW, IJzerman MJ. Detecting blood-based biomarkers in metastatic breast cancer: a systematic review of their current status and clinical utility. Int J Mol Sci. 2017;18(2) 10.3390/ijms18020363. - PMC - PubMed

[6] Berghuis AM, Koffijberg H, Prakash J, Terstappen LW, IJzerman MJ. Detecting blood-based biomarkers in metastatic breast cancer: a systematic review of their current status and clinical utility. Int J Mol Sci. 2017;18(2) 10.3390/ijms18020363. - PMC - PubMed

[7] Ulrich BC, Paweletz CP. Cell-free DNA in oncology: gearing up for clinic. Ann Lab Med. 2018;38:1–8. doi: 10.3343/alm.2018.38.1.1. - DOI - PMC - PubMed

[8] Ulrich BC, Paweletz CP. Cell-free DNA in oncology: gearing up for clinic. Ann Lab Med. 2018;38:1–8. doi: 10.3343/alm.2018.38.1.1. - DOI - PMC - PubMed

[9] Cohen JD, Li L, Wang Y, Thoburn C, Afsari B, Danilova L, et al. Detection and localization of surgically resectable cancers with a multi-analyte blood test. Science. 2018;359:926–930. doi: 10.1126/science.aar3247. - DOI - PMC - PubMed

[10] Cohen JD, Li L, Wang Y, Thoburn C, Afsari B, Danilova L, et al. Detection and localization of surgically resectable cancers with a multi-analyte blood test. Science. 2018;359:926–930. doi: 10.1126/science.aar3247. - DOI - PMC - PubMed

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Advances in liquid biopsy approaches for early detection and monitoring of cancer

Affiliations

Advances in liquid biopsy approaches for early detection and monitoring of cancer

Authors

Affiliations

Abstract

Conflict of interest statement

Competing interests

Publisher’s Note

Similar articles

Cited by

References

MeSH terms

LinkOut - more resources

Full Text Sources

Other Literature Sources

Abstract

Conflict of interest statement

Competing interests

Publisher’s Note

Similar articles

Cited by

References

MeSH terms

Related information

LinkOut - more resources

Full Text Sources

Other Literature Sources